10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

ERVK-7 Blocking Peptide (N-Term)

Synthetic peptide
Catalog # BP21832a

Specification

ERVK-7 Blocking Peptide (N-Term) - Product Information

Primary Accession P61567

ERVK-7 Blocking Peptide (N-Term) - Additional Information

Other Names
Endogenous retrovirus group K member 7 Env polyprotein, Envelope polyprotein, HERV-K(III) envelope protein, HERV-K102 envelope protein, HERV-K_1q22 provirus ancestral Env polyprotein, Surface protein, SU, Transmembrane protein, TM, ERVK-7

Target/Specificity
The synthetic peptide sequence is selected from aa 116-128 of HUMAN ERVK-7

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

ERVK-7 Blocking Peptide (N-Term) - Protein Information

Name ERVK-7

Function
Retroviral envelope proteins mediate receptor recognition and membrane fusion during early infection. Endogenous envelope proteins may have kept, lost or modified their original function during evolution. TM anchors the envelope heterodimer to the viral membrane through one transmembrane domain. The other hydrophobic domain, called fusion peptide, mediates fusion of the viral membrane with the target cell membrane (By similarity).

Cellular Location
Virion.

Tissue Location
Expressed in lung, placenta, testis and peripheral blood lymphocytes.

ERVK-7 Blocking Peptide (N-Term) - Protocols

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

ERVK-7 Blocking Peptide (N-Term) - Images

ERVK-7 Blocking Peptide (N-Term) - Background

Retroviral envelope proteins mediate receptor recognition and membrane fusion during early infection. Endogenous envelope proteins may have kept, lost or modified their original function during evolution. TM anchors the envelope heterodimer to the viral membrane through one transmembrane domain. The other hydrophobic domain, called fusion peptide, mediates fusion of the viral membrane with the target cell membrane (By similarity).

ERVK-7 Blocking Peptide (N-Term) - References

Barbulescu M.,et al.Curr. Biol. 9:861-868(1999).
Sugimoto J.,et al.Genomics 72:137-144(2001).
Wang-Johanning F.,et al.Oncogene 22:1528-1535(2003).